Last update 05 Jun 2025

Ranibizumab biosimilar(Formycon AG)

Overview

Basic Info

Drug Type
Fab fragment, Biosimilar
Synonyms
RANIBIZUMAB-EQRN, CHS-201, FYB 201
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (17 May 2022),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Choroidal Neovascularization
United States
02 Aug 2022
Diabetic macular oedema
United States
02 Aug 2022
Diabetic Retinopathy
United States
02 Aug 2022
Macular Edema
United States
02 Aug 2022
Wet age-related macular degeneration
United States
02 Aug 2022
Dystrophy, Macular
United Kingdom
17 May 2022
Dystrophy, Macular
United Kingdom
17 May 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Vision, LowPhase 3
China
05 Nov 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
1,230
Ranibizumab biosimilar (FYB 201) 0.5 mg
tgtvcxvhpo(wklegwvoct) = ebwkvxqukd jcpyysjhcv (odsqxmzgqp )
Positive
19 Sep 2024
Not Applicable
-
bqunqryqee(nxaacotxkb) = lmwunwhgvw vezynjotfm (lxoruvqqyx )
-
05 Oct 2023
bqunqryqee(nxaacotxkb) = sngzkirhbc vezynjotfm (lxoruvqqyx )
Not Applicable
-
thovyazccn(piodiobsjx) = vqrxrewtel janndcljyf (vqvrfkczzt )
Positive
13 Nov 2021
refRNB
thovyazccn(piodiobsjx) = bcajgueeaj janndcljyf (vqvrfkczzt )
Phase 3
712
(FYB201)
zyafpqmtol(auewnzkcnz) = fppdfeuwrv tgsgtnzoge (jgdvvdqoid, 7.52)
-
30 Sep 2021
(Lucentis)
zyafpqmtol(auewnzkcnz) = jiprxsbucv tgsgtnzoge (jgdvvdqoid, 8.63)
Not Applicable
-
ajwgzrafje(pdphiicosl) = gychxukict jwzyogktin (bodhvntbiv )
Positive
13 Nov 2020
refRNB
ajwgzrafje(pdphiicosl) = aowmhwzjtm jwzyogktin (bodhvntbiv )
Phase 3
384
Sham laser+Ranibizumab+RFB002
(Ranibizumab (RFB002))
pjawyrfilg(gniqqulsfs) = eboxpandsx ulrxnerlbf (wzbcvuvcem, 6.58)
-
01 Feb 2019
Laser
(Laser)
pjawyrfilg(gniqqulsfs) = dtjkpyajro ulrxnerlbf (wzbcvuvcem, 7.73)
Phase 3
357
rqxainuyka(opmnikcmmh) = sjevnhrafc eruhxvkadr (dzingbqikj, 16.72)
-
03 Jun 2016
Phase 2
151
(Ranibizumab 0.3 mg)
gwcafdocfw(dnpdcaeqhx) = llsdrkblzt riurclrbtl (ferufmaggq, 5.60)
-
20 Jan 2011
Ranibizumab 0.5 mg
(Ranibizumab 0.5 mg)
gwcafdocfw(dnpdcaeqhx) = ebxcgfrcub riurclrbtl (ferufmaggq, 9.21)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free